scholarly journals A shared susceptibility locus in p53 for both gastric cancer and esophageal cancer in a northwestern Chinese population

2019 ◽  
Author(s):  
Juan Cao ◽  
Zhiqiang Chen ◽  
Jing Chen ◽  
Yanjie You ◽  
Chaoyong Tian ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Genetic Variants ◽  
Genetic Locus ◽  
Immunohistochemical Method ◽  
Regression Analyses ◽  
Gastrointestinal Cancers ◽  
P53 Expression ◽  
Increased Risk ◽  
Upper Gastrointestinal

Abstract Background Upper gastrointestinal cancers are the leading causes of cancer-related deaths in Northwest China and share many similarities in terms of histological type, risk factors and genetic variants. We hypothesized that shared common genetic SNPs among eight SNPs in the p53 pathway existed among Ningxia gastric cancer (GC) and esophageal cancer (EC) patients. Methods A total of 180 GC cases, 113 EC cases and 358 cancer-free control subjects from a high-incidence area for upper gastrointestinal cancers in Ningxia, China, were enrolled in this study. The genotyping of 8 SNPs was performed using PCR direct sequencing. P53 expression in GC and EC tissues was examined using the S-P immunohistochemical method. Multiple logistic regression analyses were used to estimate the association between genotypes and GC or EC risks. Kaplan-Meier and multivariate Cox regression analyses were carried out to evaluate the associations between genetic variants and overall survival. Result rs1042522 was a common genetic locus shared by both Ningxia GC and EC patients. Compared with the rs1042522 Pro allele, the rs1042522 Arg allele increased the GC risk by 1.810 times and the EC risk by 2.285 times. Additionally, patients who carried the rs1042522 Arg allele and who also smoked or consumed alcohol had an increased risk for GC and EC. Cox survival analysis showed that neither p53 nor rs1042522 had an effect on the prognosis of GC and EC patients. Conclusion rs1042522 was a common genetic locus responsible for susceptibility shared by both northwestern GC and EC Chinese patients. Tobacco smoking and alcohol drinking further enhanced the cancer risk in our study.

Proton pump inhibitors and upper gastrointestinal cancers

2019 ◽  
Vol 12 (9) ◽  
pp. 526-530
Author(s):  
Monica Kumar
Keyword(s):  
Gastric Cancer ◽  
General Practice ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cost Effective ◽  
Gastrointestinal Cancers ◽  
Increased Risk ◽  
The Uk ◽  
Upper Gastrointestinal

Proton pump inhibitors (PPIs) were introduced in the 1980s. They are now one of the most commonly prescribed drugs in general practice. They are cost-effective when used correctly; however, PPIs are often used beyond accepted clinical indications. Recent published studies performed outside the UK have suggested that adverse effects are associated with long-term use of PPIs; in particular, an increased risk of gastric cancer. This article will aim to systematically assess the evidence and discuss its application to our clinical practice.

Prevalence-adjusted trends in U.S. healthcare spending on upper gastrointestinal cancers, 1996 to 2016.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16064-e16064
Author(s):  
Igor Stukalin ◽  
Newaz Shubidito Ahmed ◽  
Adam Michael Fundytus ◽  
Siddharth Singh ◽  
Christopher Ma
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Stomach Cancer ◽  
Inpatient Care ◽  
Healthcare Spending ◽  
Gastrointestinal Cancers ◽  
The Us ◽  
Capita Spending ◽  
Per Capita ◽  
Upper Gastrointestinal

e16064 Background: Upper gastrointestinal cancers are rising in prevalence and associated with high healthcare costs. We estimated trends in the US healthcare spending in patients with esophageal and stomach cancer between 1996 and 2016. Methods: We used data on national healthcare spending developed by the Institute for Health Metrics and Evaluations Disease Expenditure Project. Corresponding prevalence of esophageal and stomach cancer was estimated from the Global Burden of Diseases Study. Prevalence-adjusted, temporal trends in the US healthcare spending in patients with upper gastrointestinal cancer, stratified by age and setting of care (ambulatory, inpatient, emergency department, pharmaceutical prescriptions, nursing care and government administration) were calculated using joinpoint regression, expressed as annual percent change (APC) with 95% confidence intervals. Results: Overall, annual US healthcare spending on esophageal cancer increased from $0.76 billion (95% CI 0.68-0.86) in 1996 to $1.06 billion (95% CI 0.88-1.29) in 2016, although after adjusting for increasing prevalence, there was a significant decrease in per capita spending of -0.4%/year (95% CI -0.7%, -0.1%). Annual US healthcare spending on stomach cancer increased from $1.23 billion (95% CI $1.14 billion - $1.34 billion) in 1996 to $1.49 billion (95% CI $1.20 billion - $2.03 billion) in 2016. Per capita spending increased by 1.8%/year (95% CI 1.4%, 2.1%) between 1996 and 2011, followed by a decrease in gastric cancer-related per capita spending after 2011 (APC -4.4%/year [95% CI -5.8%, -2.9%]). Inpatient care was the largest contributor to total cost of both cancers between 1996-2016: 61.9% for esophageal cancer and 73.1% in gastric cancer in 2016. The rising price and intensity of care (defined as the cost per encounter) was the largest driver of change from 1996-2016 for both cancers, accounting for $0.28 billion (95% CI 0.12-0.41) for esophageal cancer and $0.95 billion (95% CI 0.41-1.39) for stomach cancer. Conclusions: After adjusting for rising prevalence, US per capita healthcare spending on esophageal cancer has decreased significantly since 1996, while per capita spending on gastric cancer has remained stable. Inpatient care was the most significant contributor to costs for both cancers over the time period studied.

Susceptible genes of restless legs syndrome in migraine

Cephalalgia ◽  
2016 ◽  
Vol 36 (11) ◽  
pp. 1028-1037 ◽  
Author(s):  
Jong-Ling Fuh ◽  
Ming-Yi Chung ◽  
Shu-Chih Yao ◽  
Ping-Kun Chen ◽  
Yi-Chu Liao ◽  
...  
Keyword(s):  
Restless Legs Syndrome ◽  
Genetic Variants ◽  
Multivariate Regression ◽  
Iron Homeostasis ◽  
Nucleotide Polymorphisms ◽  
Regression Analyses ◽  
Single Nucleotide ◽  
Association Analyses ◽  
Restless Legs ◽  
Increased Risk

Objective Several genetic variants have been found to increase the risk of restless legs syndrome (RLS). The aim of the present study was to determine if these genetic variants were also associated with the comorbidity of RLS and migraine in patients. Methods Thirteen single-nucleotide polymorphisms (SNPs) at six RLS risk loci ( MEIS1, BTBD9, MAP2K5, PTPRD, TOX3, and an intergenic region on chromosome 2p14) were genotyped in 211 migraine patients with RLS and 781 migraine patients without RLS. Association analyses were performed for the overall cohort, as well as for the subgroups of patients who experienced migraines with and without aura and episodic migraines (EMs) vs. chronic migraines (CMs). In order to verify which genetic markers were potentially related to the incidence of RLS in migraine patients, multivariate regression analyses were also performed. Results Among the six tested loci, only MEIS1 was significantly associated with RLS. The most significant SNP of MEIS1, rs2300478, increased the risk of RLS by 1.42-fold in the overall cohort ( p = 0.0047). In the subgroup analyses, MEIS1 augmented the risk of RLS only in the patients who experienced EMs (odds ratio (OR) = 1.99, p = 0.0004) and not those experiencing CMs. Multivariate regression analyses further showed that rs2300478 in MEIS1 (OR = 1.39, p = 0.018), a CM diagnosis (OR = 1.52, p = 0.022), and depression (OR = 1.86, p = 0.005) were independent predictors of RLS in migraine. Conclusions MEIS1 variants were associated with an increased risk of RLS in migraine patients. It is possible that an imbalance in iron homeostasis and the dopaminergic system may represent a link between RLS incidence and migraines.

scholarly journals Genetic Variants in PTGS1 and NOS3 Genes Increase the Risk of Upper Gastrointestinal Bleeding: A Case–Control Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Marcela Forgerini ◽  
Gustavo Urbano ◽  
Tales Rubens de Nadai ◽  
Sabrina Setembre Batah ◽  
Alexandre Todorovic Fabro ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gastrointestinal Bleeding ◽  
Genetic Variants ◽  
Case Control Study ◽  
Upper Gastrointestinal Bleeding ◽  
Case Control ◽  
Gastrointestinal Disorders ◽  
Increased Risk ◽  
Upper Gastrointestinal ◽  
Control Study

Objective: To assess the association between PTGS1 and NOS3 variant alleles and the risk to develop upper gastrointestinal bleeding (UGIB) secondary to complicated peptic disease.Methods: A case–control study was conducted in a Brazilian complex hospital from July 2016 to March 2020. Case: Patients with UGIB diagnosis. Control: Patients admitted for surgery not related to gastrointestinal disorders. Variables: UGIB (outcome), genetic variants in PTGS1 and NOS3 genes (independent), and sex, age, schooling, ethnicity, previous history of gastrointestinal disorders, Helicobacter pylori serology, comorbidity, drug therapy, and lifestyle (confounding). The single-nucleotide polymorphisms (SNPs) of the PTSG1 gene (rs1330344, rs3842787, rs10306114, and rs5788) and NOS3 gene (rs2070744 and rs1799983) were determined using the real-time polymerase chain reaction. Helicobacter pylori serology was determined through the chemiluminescence technique. Logistic regression models were built and deviations of allelic frequencies from Hardy–Weinberg equilibrium were verified.Results: 200 cases and 706 controls were recruited. Carriers of the AG genotype of rs10306114 (OR: 2.55, CI 95%: 1.13–5.76) and CA + AA genotypes of rs5788 (OR: 2.53, CI 95%: 1.14–5.59) were associated with an increased risk for the UGIB development. In nonsteroidal anti-inflammatory drugs (NSAIDs) users, the six variants evaluated modified the magnitude of the risk of UGIB, whereas in low-dose aspirin (LDA) users, an increased risk of UGIB was observed for four of them (rs1330344, rs10306114, rs2070744, and rs1799983). Personal ulcer history (p-value: < 0.001); Helicobacter pylori infection (p-value: < 0.011); NSAIDs, LDA, and oral anticoagulant use (p-value: < 0.001); and alcohol intake (p-value: < 0.001) were also identified as independent risk factors for UGIB.Conclusion: This study presents two unprecedented analyses within the scope of the UGIB (rs10306114 and rs2070744), and our findings showing an increased risk of UGIB in the presence of the genetic variants rs10306114 and rs5788, regardless of the drug exposure. Besides, the presence of the evaluated variants might modify the magnitude of the risk of UGIB in LDA/NSAIDs users. Therefore, our data suggest the need for a personalized therapy and drug use monitoring in order to promote patient safety.

scholarly journals Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer

2011 ◽  
Vol 33 (1) ◽  
pp. 119-123 ◽  
Author(s):  
L. Liu ◽  
C. Zhou ◽  
L. Zhou ◽  
L. Peng ◽  
D. Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Hepatocellular Carcinoma ◽  
Esophageal Cancer ◽  
Genetic Variants

Noneffectiveness of scopolamine for facilitating detection of upper gastrointestinal neoplasia during screening esophagogastroduodenoscopy: propensity score-matched study

Endoscopy ◽  
2020 ◽  
Vol 52 (07) ◽  
pp. 556-562
Author(s):  
Fumio Omata ◽  
Yasuhisa Kumakura ◽  
Naoki Ishii ◽  
Gautam A. Deshpande ◽  
Kohei Matoba ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Esophageal Cancer ◽  
Propensity Score ◽  
Controlled Trial ◽  
Lesion Detection ◽  
Smoking History ◽  
Bivariate Analysis ◽  
Gastric Adenoma ◽  
Duodenal Adenoma ◽  
Upper Gastrointestinal

Background Antispasmodics, such as scopolamine, are widely used in several countries prior to diagnostic and screening esophagogastroduodenoscopy (EGD), with the goal of optimizing the detection of minute lesions, typically early gastric cancer (T1 lesions). The aim of this study was to determine whether scopolamine facilitates detection of gastric cancer in the screening setting. Methods A propensity score-matched retrospective study was conducted in a tertiary referral medical center in Tokyo, Japan. Consecutive individuals (n = 40 776) underwent screening EGD between January 2011 and May 2016. All outcome lesions were diagnosed with histopathological confirmation. Detection of esophageal cancer, gastric adenoma, duodenal adenoma, and upper gastrointestinal neoplasia (UGIN) were investigated as secondary outcomes. Results Scopolamine was used in 31 130 patients (76.3 %) and propensity score matching yielded 6625 pairs. Bivariate analysis revealed no significant association between possible confounders (age, sex, overweight, atrophic gastritis, alcohol history, smoking history, midazolam use, endoscopist biopsy rate grade, and gastric cancer in first-degree relatives) and scopolamine use. Lesions detected were 18 gastric cancers, 11 esophageal cancers, 19 gastric adenomas, 6 duodenal adenomas, and 54 UGINs, with no significant association between scopolamine use and lesion detection. Conclusions Scopolamine use did not appear to effectively facilitate detection of gastric or esophageal cancer, gastric or duodenal adenoma, and UGIN during screening EGD. Scopolamine should be avoided until its efficacy is confirmed by a randomized controlled trial.

scholarly journals Diagnostic Performance of Artificial Intelligence-Centred Systems in the Diagnosis and Postoperative Surveillance of Upper Gastrointestinal Malignancies Using Computed Tomography Imaging: A Systematic Review and Meta-Analysis of Diagnostic Accuracy

2021 ◽  
Author(s):  
Swathikan Chidambaram ◽  
Viknesh Sounderajah ◽  
Nick Maynard ◽  
Sheraz R. Markar
Keyword(s):  
Artificial Intelligence ◽  
Gastric Cancer ◽  
Systematic Review ◽  
Esophageal Cancer ◽  
Diagnostic Accuracy ◽  
Diagnostic Performance ◽  
Meta Analysis ◽  
Diagnostic Methods ◽  
Gastrointestinal Malignancies ◽  
Upper Gastrointestinal

Abstract Background Upper gastrointestinal cancers are aggressive malignancies with poor prognosis, even following multimodality therapy. As such, they require timely and accurate diagnostic and surveillance strategies; however, such radiological workflows necessitate considerable expertise and resource to maintain. In order to lessen the workload upon already stretched health systems, there has been increasing focus on the development and use of artificial intelligence (AI)-centred diagnostic systems. This systematic review summarizes the clinical applicability and diagnostic performance of AI-centred systems in the diagnosis and surveillance of esophagogastric cancers. Methods A systematic review was performed using the MEDLINE, EMBASE, Cochrane Review, and Scopus databases. Articles on the use of AI and radiomics for the diagnosis and surveillance of patients with esophageal cancer were evaluated, and quality assessment of studies was performed using the QUADAS-2 tool. A meta-analysis was performed to assess the diagnostic accuracy of sequencing methodologies. Results Thirty-six studies that described the use of AI were included in the qualitative synthesis and six studies involving 1352 patients were included in the quantitative analysis. Of these six studies, four studies assessed the utility of AI in gastric cancer diagnosis, one study assessed its utility for diagnosing esophageal cancer, and one study assessed its utility for surveillance. The pooled sensitivity and specificity were 73.4% (64.6–80.7) and 89.7% (82.7–94.1), respectively. Conclusions AI systems have shown promise in diagnosing and monitoring esophageal and gastric cancer, particularly when combined with existing diagnostic methods. Further work is needed to further develop systems of greater accuracy and greater consideration of the clinical workflows that they aim to integrate within.

scholarly journals Evaluation of the Prevalence of Upper Gastrointestinal Cancers in Khorramadad

2021 ◽  
Author(s):  
Saleh Azadbakht ◽  
Morteza Azadbakht ◽  
Salehe Azadbakht
Keyword(s):  
Esophageal Cancer ◽  
Gastrointestinal Cancer ◽  
Distal Part ◽  
Demographic Data ◽  
Histopathological Analysis ◽  
Gastrointestinal Cancers ◽  
Upper Gastrointestinal Cancer ◽  
Regional Population ◽  
The Mean ◽  
Upper Gastrointestinal

Abstract BackgroundGastrointestinal cancer is one of the leading causes of cancer-related deaths and its incidence varies based on geographical, demographic, genetic and clinical factors. In this study, we aim to investigate the frequency of upper gastrointestinal cancers in patients referred to the endoscopy department Shohada Ashayer and Shahid Rahimi Hospital of Khorramabad from 2015-2019.MethodsThis research is a descriptive observational study where patients suspected for gastrointestinal cancer were included. These patients underwent endoscopy where samples from suspected cancer patient were subjected to histopathological analysis for confirmation. Demographic data along with the findings from endoscopy and pathology and details regarding the lesions (type and location) and the causes of lesions were recorded in the checklist for all the patients. ResultsOf 1274 patients, 630 (49/5%) were male and 644 (50/5%) were female. The mean age of the patients was 50 years. The Frequency of stomach cancer was 194 (16.7%) and that of esophageal cancer was 123 (9.7%).The most common type of pathology in esophageal cancer was squamous cell carcinoma with 91 cases (73.9%) and in the stomach were all cases were of adenocarcinoma. The distal part of the esophagus was most affected, 88 cases (72.2%) and cardiac end in the stomach. with 98 cases (50.5%) . The frequency of cancer was significantly higher in men and in patients aged above 60 years, p<0.05, respectively.ConclusionAccording to the results of the study, gastric cancer is the most common upper gastrointestinal cancer in regional population, followed by esophageal cancer.

scholarly journals Obesity Is Associated with Early Onset of Gastrointestinal Cancers in California

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Yen-Yi Juo ◽  
Melinda A. Maggard Gibbons ◽  
Erik Dutson ◽  
Anne Y. Lin ◽  
Jane Yanagawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Pancreatic Cancer ◽  
Morbid Obesity ◽  
Esophageal Cancer ◽  
Onset Age ◽  
Gastrointestinal Cancers ◽  
Cross Sectional ◽  
Gi Cancer ◽  
Cancer Types

Background. Although it is well known that obesity is a risk factor for gastrointestinal (GI) cancer, it is not well established if obesity can cause earlier GI cancer onset. Methods. A cross-sectional study examining the linked 2004–2008 California Cancer Registry Patient Discharge Database was performed to evaluate the association between obesity and onset age among four gastrointestinal cancers, including esophageal, gastric, pancreatic, and colorectal cancers. Regression models were constructed to adjust for other carcinogenic factors. Results. The diagnosis of obesity (BMI > 30) was associated with a reduction in diagnosis age across all four cancer types: 3.25 ± 0.53 years for gastric cancer, 4.56 ± 0.18 years for colorectal cancer, 4.73 ± 0.73 years for esophageal cancer, and 5.35 ± 0.72 for pancreatic cancer. The diagnosis of morbid obesity (BMI > 40) was associated with a more pronounced reduction in the age of diagnosis: 5.48 ± 0.96 years for gastric cancer, 7.75 ± 0.30 years for colorectal cancer, 7.67 ± 1.26 years for esophageal cancer, and 8.19 ± 1.25 years for pancreatic cancer. Both morbid obesity and obesity remained strongly associated with earlier cancer diagnosis for all four cancer types even after adjusting for other available cancer risk factors. Conclusions. The diagnosis of obesity, especially morbid obesity, was associated with a significantly earlier gastrointestinal cancer onset in California. Further research with prospective cohort data may be required to establish the causal relationship between obesity and cancer onset age.

scholarly journals Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers

2015 ◽  
Vol 44 (4) ◽  
pp. 1341-1352 ◽  
Author(s):  
Hyuna Sung ◽  
Howard H Yang ◽  
Han Zhang ◽  
Qi Yang ◽  
Nan Hu ◽  
...  
Keyword(s):  
Genetic Variants ◽  
Gastrointestinal Cancers ◽  
Common Genetic Variants ◽  
Epigenetic Machinery ◽  
Upper Gastrointestinal
Sign in / Sign up

Export Citation Format

Share Document